New directions in thrombolytic therapy. Molecular mutants and biochemical conjugates

Douglas E. Vaughan; Joseph Loscalzo

doi:10.1016/1050-1738(91)90057-L

New directions in thrombolytic therapy. Molecular mutants and biochemical conjugates

Douglas E. Vaughan^*, Joseph Loscalzo

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Short survey › peer-review

1 Scopus citations

Abstract

The currently available thrombolytic agents are widely perceived to be suboptimal in terms of both efficacy and safety. This perception has in turn stimulated efforts to design and construct novel plasminogen activators endowed with improved biochemical and pharmacologic properties. There is as yet no consensus as to the properties of an "ideal" thrombolytic agent, and the failure of comparative clinical trials to identify a superior agent has contributed to the controversy. Although an improved plasminogen activator has not yet been constructed, it is clear that efforts to do so have advanced our knowledge of the complex structure-function relationships within plasminogen activators.

Original language	English (US)
Pages (from-to)	36-39
Number of pages	4
Journal	Trends in Cardiovascular Medicine
Volume	1
Issue number	1
DOIs	https://doi.org/10.1016/1050-1738(91)90057-L
State	Published - 1991

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/1050-1738(91)90057-L

Fingerprint Dive into the research topics of 'New directions in thrombolytic therapy. Molecular mutants and biochemical conjugates'. Together they form a unique fingerprint.

Cite this

@article{df63163d5cb042bc9b1180d862c08cbe,

title = "New directions in thrombolytic therapy. Molecular mutants and biochemical conjugates",

abstract = "The currently available thrombolytic agents are widely perceived to be suboptimal in terms of both efficacy and safety. This perception has in turn stimulated efforts to design and construct novel plasminogen activators endowed with improved biochemical and pharmacologic properties. There is as yet no consensus as to the properties of an {"}ideal{"} thrombolytic agent, and the failure of comparative clinical trials to identify a superior agent has contributed to the controversy. Although an improved plasminogen activator has not yet been constructed, it is clear that efforts to do so have advanced our knowledge of the complex structure-function relationships within plasminogen activators.",

author = "Vaughan, {Douglas E.} and Joseph Loscalzo",

note = "Funding Information: This work was supported by grants HL40411 and HL43344 from the Na tional Institutes of Health . Douglas E . Vaughan is the recipient of a Clinician-Scientist Award from the American Heart Association, Dallas, Texas, and a Research Advisory Group Award from the Veterans Administration . Joseph Loscalzo is the recipient of a Research Career Development Award (K04HL02273) from the National Institutes of Health and a Research Advisory Group Award from the Veterans Administration . The authors wish to thank Ms . S . Tribuna for excellent secretarial support .",

year = "1991",

doi = "10.1016/1050-1738(91)90057-L",

language = "English (US)",

volume = "1",

pages = "36--39",

journal = "Trends in Cardiovascular Medicine",

issn = "1050-1738",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - New directions in thrombolytic therapy. Molecular mutants and biochemical conjugates

AU - Vaughan, Douglas E.

AU - Loscalzo, Joseph

N1 - Funding Information: This work was supported by grants HL40411 and HL43344 from the Na tional Institutes of Health . Douglas E . Vaughan is the recipient of a Clinician-Scientist Award from the American Heart Association, Dallas, Texas, and a Research Advisory Group Award from the Veterans Administration . Joseph Loscalzo is the recipient of a Research Career Development Award (K04HL02273) from the National Institutes of Health and a Research Advisory Group Award from the Veterans Administration . The authors wish to thank Ms . S . Tribuna for excellent secretarial support .

PY - 1991

Y1 - 1991

N2 - The currently available thrombolytic agents are widely perceived to be suboptimal in terms of both efficacy and safety. This perception has in turn stimulated efforts to design and construct novel plasminogen activators endowed with improved biochemical and pharmacologic properties. There is as yet no consensus as to the properties of an "ideal" thrombolytic agent, and the failure of comparative clinical trials to identify a superior agent has contributed to the controversy. Although an improved plasminogen activator has not yet been constructed, it is clear that efforts to do so have advanced our knowledge of the complex structure-function relationships within plasminogen activators.

AB - The currently available thrombolytic agents are widely perceived to be suboptimal in terms of both efficacy and safety. This perception has in turn stimulated efforts to design and construct novel plasminogen activators endowed with improved biochemical and pharmacologic properties. There is as yet no consensus as to the properties of an "ideal" thrombolytic agent, and the failure of comparative clinical trials to identify a superior agent has contributed to the controversy. Although an improved plasminogen activator has not yet been constructed, it is clear that efforts to do so have advanced our knowledge of the complex structure-function relationships within plasminogen activators.

UR - http://www.scopus.com/inward/record.url?scp=0025767042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025767042&partnerID=8YFLogxK

U2 - 10.1016/1050-1738(91)90057-L

DO - 10.1016/1050-1738(91)90057-L

M3 - Short survey

C2 - 21239344

AN - SCOPUS:0025767042

VL - 1

SP - 36

EP - 39

JO - Trends in Cardiovascular Medicine

JF - Trends in Cardiovascular Medicine

SN - 1050-1738

IS - 1

ER -

New directions in thrombolytic therapy. Molecular mutants and biochemical conjugates

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this